Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 158 entries
Sorted by: Best Match Show Resources per page
[The Fixed Combination of Perindopril A/Amlodipine a Rational Choice to Iimprove the Control of Hypertension in Clinical Practice (results of the program Konstant)].

Kardiologiia

Kobalava ZD, Kotovskaya YV, Khodorovich On Behalf Of The Doctors Participants In The Program Konstant Observational Program NA.
PMID: 28294837
Kardiologiia. 2015 Mar;55(3):10-16.

No abstract available.

Cite
Kobalava ZD, Kotovskaya YV, Khodorovich On Behalf Of The Doctors Participants In The Program Konstant Observational Program NA. [The Fixed Combination of Perindopril A/Amlodipine a Rational Choice to Iimprove the Control of Hypertension in Clinical Practice (results of the program Konstant)]. Kardiologiia. 2015;55(3):10-16
Kobalava, Z. D., Kotovskaya, Y. V., & Khodorovich On Behalf Of The Doctors Participants In The Program Konstant Observational Program, N. A. (2015). [The Fixed Combination of Perindopril A/Amlodipine a Rational Choice to Iimprove the Control of Hypertension in Clinical Practice (results of the program Konstant)]. Kardiologiia, 55(3), 10-16.
Kobalava, Z D, et al. "[The Fixed Combination of Perindopril A/Amlodipine a Rational Choice to Iimprove the Control of Hypertension in Clinical Practice (results of the program Konstant)]." Kardiologiia vol. 55,3 (2015): 10-16.
Kobalava ZD, Kotovskaya YV, Khodorovich On Behalf Of The Doctors Participants In The Program Konstant Observational Program NA. [The Fixed Combination of Perindopril A/Amlodipine a Rational Choice to Iimprove the Control of Hypertension in Clinical Practice (results of the program Konstant)]. Kardiologiia. 2015 Mar;55(3):10-16. Russian. PMID: 28294837.
Copy Download .nbib Format: NLM
Notice of Retraction: Ahimastos AA, et al. Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial. JAMA. 2007;298(13):1539-1547.

JAMA

[No authors listed]
PMID: 26594834
JAMA. 2015 Dec 22-29;314(24):2692-3. doi: 10.1001/jama.2015.16678.

No abstract available.

Cite
Notice of Retraction: Ahimastos AA, et al. Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial. JAMA. 2007;298(13):1539-1547. JAMA. 2015;314(24):2692-3doi: 10.1001/jama.2015.16678.
(2015). Notice of Retraction: Ahimastos AA, et al. Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial. JAMA. 2007;298(13):1539-1547. JAMA, 314(24), 2692-3. https://doi.org/10.1001/jama.2015.16678
"Notice of Retraction: Ahimastos AA, et al. Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial. JAMA. 2007;298(13):1539-1547." JAMA vol. 314,24 (2015): 2692-3. doi: https://doi.org/10.1001/jama.2015.16678
Notice of Retraction: Ahimastos AA, et al. Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial. JAMA. 2007;298(13):1539-1547. JAMA. 2015 Dec 22-29;314(24):2692-3. doi: 10.1001/jama.2015.16678. PMID: 26594834.
Copy Download .nbib Format: NLM
Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study.

Current therapeutic research, clinical and experimental

Sekuri C, Bayturan O, Gocer H, Tavli T, Tezcan UK.
PMID: 24944419
Curr Ther Res Clin Exp. 2003 Nov;64(9):715-24. doi: 10.1016/j.curtheres.2003.11.005.

BACKGROUND: Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a diuretic has been shown to be highly effective in hypertension. Clinical trials have demonstrated that ACE inhibitors may improve endothelial cell dysfunction in hypertension. However, the effectiveness of...

Cite
Sekuri C, Bayturan O, Gocer H, et al. Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study. Curr Ther Res Clin Exp. 2003;64(9):715-24doi: 10.1016/j.curtheres.2003.11.005.
Sekuri, C., Bayturan, O., Gocer, H., Tavli, T., & Tezcan, U. K. (2003). Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study. Current therapeutic research, clinical and experimental, 64(9), 715-24. https://doi.org/10.1016/j.curtheres.2003.11.005
Sekuri, Cevad, et al. "Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study." Current therapeutic research, clinical and experimental vol. 64,9 (2003): 715-24. doi: https://doi.org/10.1016/j.curtheres.2003.11.005
Sekuri C, Bayturan O, Gocer H, Tavli T, Tezcan UK. Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study. Curr Ther Res Clin Exp. 2003 Nov;64(9):715-24. doi: 10.1016/j.curtheres.2003.11.005. PMID: 24944419; PMCID: PMC4053063.
Copy Download .nbib Format: NLM
Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.

Clinical drug investigation

Seedat YK, Randeree IG.
PMID: 18370544
Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007.

OBJECTIVE: This study compared the antihypertensive effect and acceptability of a perindopril-based group with that of an atenolol-based group in Indian hypertensive type 2 (non-insulin-dependent) diabetic patients.DESIGN AND SETTING: 100 ambulant patients aged between 35 and 69 years were...

Cite
Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40doi: 10.2165/00044011-199816030-00007.
Seedat, Y. K., & Randeree, I. G. (1998). Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clinical drug investigation, 16(3), 229-40. https://doi.org/10.2165/00044011-199816030-00007
Seedat, Y K, and Randeree, I G. "Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol." Clinical drug investigation vol. 16,3 (1998): 229-40. doi: https://doi.org/10.2165/00044011-199816030-00007
Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007. PMID: 18370544.
Copy Download .nbib Format: NLM
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension.

Evidence-based medicine

Zarnke KB.
PMID: 17213072
Evid Based Med. 2006 Apr;11(2):42. doi: 10.1136/ebm.11.2.42.

No abstract available.

Cite
Zarnke KB. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Evid Based Med. 2006;11(2):42doi: 10.1136/ebm.11.2.42.
Zarnke, K. B. (2006). Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Evidence-based medicine, 11(2), 42. https://doi.org/10.1136/ebm.11.2.42
Zarnke, Kelly B. "Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension." Evidence-based medicine vol. 11,2 (2006): 42. doi: https://doi.org/10.1136/ebm.11.2.42
Zarnke KB. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Evid Based Med. 2006 Apr;11(2):42. doi: 10.1136/ebm.11.2.42. PMID: 17213072.
Copy Download .nbib Format: NLM
Is it beneficial to treat hypertension in patients aged 80 years or older?.

Nature clinical practice. Nephrology

Ritz E.
PMID: 18725915
Nat Clin Pract Nephrol. 2008 Oct;4(10):526-7. doi: 10.1038/ncpneph0916. Epub 2008 Aug 26.

Blood pressure lowering has clear beneficial effects in terms of reducing the risk of stroke, cardiovascular events and cardiovascular mortality in the general population, but it is unclear whether treating hypertension in individuals aged >or=80 years is beneficial. This...

Cite
Ritz E. Is it beneficial to treat hypertension in patients aged 80 years or older?. Nat Clin Pract Nephrol. 2008;4(10):526-7doi: 10.1038/ncpneph0916.
Ritz, E. (2008). Is it beneficial to treat hypertension in patients aged 80 years or older?. Nature clinical practice. Nephrology, 4(10), 526-7. https://doi.org/10.1038/ncpneph0916
Ritz, Eberhard. "Is it beneficial to treat hypertension in patients aged 80 years or older?." Nature clinical practice. Nephrology vol. 4,10 (2008): 526-7. doi: https://doi.org/10.1038/ncpneph0916
Ritz E. Is it beneficial to treat hypertension in patients aged 80 years or older?. Nat Clin Pract Nephrol. 2008 Oct;4(10):526-7. doi: 10.1038/ncpneph0916. Epub 2008 Aug 26. PMID: 18725915.
Copy Download .nbib Format: NLM
Perindopril: beyond lowering blood pressure.

Future cardiology

Zaiem A, Zannad F.
PMID: 19804327
Future Cardiol. 2008 May;4(3):219-35. doi: 10.2217/14796678.4.3.219.

Perindopril, a prodrug ester of perindoprilat, is an angiotensin-converting enzyme inhibitor that lowers angiotensin II and potentiates bradykinin. This agent has proven efficacy in a wide range of cardiovascular diseases. Its efficacy, safety and tolerability are well established in...

Cite
Zaiem A, Zannad F. Perindopril: beyond lowering blood pressure. Future Cardiol. 2008;4(3):219-35doi: 10.2217/14796678.4.3.219.
Zaiem, A., & Zannad, F. (2008). Perindopril: beyond lowering blood pressure. Future cardiology, 4(3), 219-35. https://doi.org/10.2217/14796678.4.3.219
Zaiem, Ahmed, and Zannad, Faiez. "Perindopril: beyond lowering blood pressure." Future cardiology vol. 4,3 (2008): 219-35. doi: https://doi.org/10.2217/14796678.4.3.219
Zaiem A, Zannad F. Perindopril: beyond lowering blood pressure. Future Cardiol. 2008 May;4(3):219-35. doi: 10.2217/14796678.4.3.219. PMID: 19804327.
Copy Download .nbib Format: NLM
A fixed combination of perindopril and indapamide reduces the risk of vascular outcomes in type 2 diabetes mellitus.

Nature clinical practice. Endocrinology & metabolism

Giles TD.
PMID: 18317478
Nat Clin Pract Endocrinol Metab. 2008 May;4(5):254-5. doi: 10.1038/ncpendmet0784. Epub 2008 Mar 04.

No abstract available.

Cite
Giles TD. A fixed combination of perindopril and indapamide reduces the risk of vascular outcomes in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2008;4(5):254-5doi: 10.1038/ncpendmet0784.
Giles, T. D. (2008). A fixed combination of perindopril and indapamide reduces the risk of vascular outcomes in type 2 diabetes mellitus. Nature clinical practice. Endocrinology & metabolism, 4(5), 254-5. https://doi.org/10.1038/ncpendmet0784
Giles, Thomas D. "A fixed combination of perindopril and indapamide reduces the risk of vascular outcomes in type 2 diabetes mellitus." Nature clinical practice. Endocrinology & metabolism vol. 4,5 (2008): 254-5. doi: https://doi.org/10.1038/ncpendmet0784
Giles TD. A fixed combination of perindopril and indapamide reduces the risk of vascular outcomes in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2008 May;4(5):254-5. doi: 10.1038/ncpendmet0784. Epub 2008 Mar 04. PMID: 18317478.
Copy Download .nbib Format: NLM
In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status.

Evidence-based medicine

Venkatachalam KL, Gandhi GY.
PMID: 19949179
Evid Based Med. 2009 Dec;14(6):177. doi: 10.1136/ebm.14.6.177.

No abstract available.

Cite
Venkatachalam KL, Gandhi GY. In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status. Evid Based Med. 2009;14(6):177doi: 10.1136/ebm.14.6.177.
Venkatachalam, K. L., & Gandhi, G. Y. (2009). In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status. Evidence-based medicine, 14(6), 177. https://doi.org/10.1136/ebm.14.6.177
Venkatachalam, K L, and Gandhi, Gunjan Y. "In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status." Evidence-based medicine vol. 14,6 (2009): 177. doi: https://doi.org/10.1136/ebm.14.6.177
Venkatachalam KL, Gandhi GY. In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status. Evid Based Med. 2009 Dec;14(6):177. doi: 10.1136/ebm.14.6.177. PMID: 19949179.
Copy Download .nbib Format: NLM
Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction.

The International journal of angiology : official publication of the International College of Angiology, Inc

Whayne TF.
PMID: 22477242
Int J Angiol. 2007;16(1):12-6. doi: 10.1055/s-0031-1278237.

Available information regarding the relation among atherosclerosis, low-density lipoproteins, markers of thrombosis, inflammation and endothelial dysfunction has accumulated, but is still very limited, making only minimal contributions to clinical decision-making. Many more clinical trials are needed, but unless there...

Cite
Whayne TF. Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction. Int J Angiol. 2007;16(1):12-6doi: 10.1055/s-0031-1278237.
Whayne, T. F. (2007). Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction. The International journal of angiology : official publication of the International College of Angiology, Inc, 16(1), 12-6. https://doi.org/10.1055/s-0031-1278237
Whayne, Thomas F. "Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction." The International journal of angiology : official publication of the International College of Angiology, Inc vol. 16,1 (2007): 12-6. doi: https://doi.org/10.1055/s-0031-1278237
Whayne TF. Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction. Int J Angiol. 2007;16(1):12-6. doi: 10.1055/s-0031-1278237. PMID: 22477242; PMCID: PMC2733000.
Copy Download .nbib Format: NLM
ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling.

Nephron extra

Westerweel PE, Joles JA, den Ouden K, Goldschmeding R, Rookmaaker MB, Verhaar MC.
PMID: 22479264
Nephron Extra. 2012 Jan;2(1):9-16. doi: 10.1159/000335750. Epub 2012 Jan 26.

BACKGROUND/AIMS: ACE inhibitor (ACE-I) treatment effectively inhibits proteinuria and ameliorates the course of various renal diseases. In experimental glomerulonephritis, however, angiotensin II (AngII) infusion has also been shown to be renoprotective. We evaluated the long-term (28 days) course of...

Cite
Westerweel PE, Joles JA, den Ouden K, et al. ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling. Nephron Extra. 2012;2(1):9-16doi: 10.1159/000335750.
Westerweel, P. E., Joles, J. A., den Ouden, K., Goldschmeding, R., Rookmaaker, M. B., & Verhaar, M. C. (2012). ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling. Nephron extra, 2(1), 9-16. https://doi.org/10.1159/000335750
Westerweel, Peter E, et al. "ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling." Nephron extra vol. 2,1 (2012): 9-16. doi: https://doi.org/10.1159/000335750
Westerweel PE, Joles JA, den Ouden K, Goldschmeding R, Rookmaaker MB, Verhaar MC. ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling. Nephron Extra. 2012 Jan;2(1):9-16. doi: 10.1159/000335750. Epub 2012 Jan 26. PMID: 22479264; PMCID: PMC3318936.
Copy Download .nbib Format: NLM
Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.

Oncology letters

Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Kawaratani H, Tsujimoto T, Fukui H.
PMID: 22870131
Oncol Lett. 2011 Jan;2(1):69-73. doi: 10.3892/ol.2010.196. Epub 2010 Oct 05.

The identification of biomarkers of anti-angiogenic therapy that predict clinical benefit is of vital importance. We previously reported that a combination treatment with clinically available safe agents, specifically angiotensin-converting enzyme inhibitor (ACE-I) and vitamin K (VK), inhibited the cumulative...

Cite
Yoshiji H, Noguchi R, Ikenaka Y, et al. Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncol Lett. 2010;2(1):69-73doi: 10.3892/ol.2010.196.
Yoshiji, H., Noguchi, R., Ikenaka, Y., Kaji, K., Shirai, Y., Aihara, Y., Yamao, J., Toyohara, M., Mitoro, A., Sawai, M., Yoshida, M., Morioka, C., Fujimoto, M., Uemura, M., Kawaratani, H., Tsujimoto, T., & Fukui, H. (2011). Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncology letters, 2(1), 69-73. https://doi.org/10.3892/ol.2010.196
Yoshiji, Hitoshi, et al. "Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents." Oncology letters vol. 2,1 (2011): 69-73. doi: https://doi.org/10.3892/ol.2010.196
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Kawaratani H, Tsujimoto T, Fukui H. Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncol Lett. 2011 Jan;2(1):69-73. doi: 10.3892/ol.2010.196. Epub 2010 Oct 05. PMID: 22870131; PMCID: PMC3412527.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 158 entries